Catalyst Wire Dossier Catalyst Wire Dossier

Ibrutinib

ibrutinib · AbbVie/Janssen
Drug timelines are a Plus or Pro feature.

173 regulatory and trial events tracked for Ibrutinib, covering 2014-02-13 to 2026-06-09. Get the full timeline:

Most recent: Clinical Trial Results: Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia [Phase 2]

See pricing